La Jolla Pharmaceutical

$3.40
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.19 (-5.29%) Today
$0.00 (0.00%) As of 8:00 PM EDT after-hours

Why Robinhood?

You can buy or sell LJPC and other stocks, options, and ETFs commission-free!

About LJPC

La Jolla Pharmaceutical Co. operates as a biopharmaceutical company, which engages in the discovery, development and commercialization of therapies intended to significantly improve outcomes in patients suffering from life-threatening diseases. Its products includes LJPC-501, LJPC-401 and LJPC-0118. Read More LJPC-501 is the proprietary formulation for angiotensin II. The LJPC-401 is the formulation of hepcidin, which is an endogenous peptide hormone and LJPC-0118 is La Jolla’s investigational product for the treatment of severe malaria. The company was founded in 1989 and is headquartered in San Diego, CA. The listed name for LJPC is La Jolla Pharmaceutical Company Common Stock.

CEO
Larry Edwards
Employees
91
Headquarters
San Diego, California
Founded
1989
Market Cap
93.03M
Price-Earnings Ratio
Dividend Yield
Average Volume
234.25K
High Today
$3.62
Low Today
$3.36
Open Price
$3.59
Volume
269.08K
52 Week High
$9.38
52 Week Low
$2.30

Collections

LJPC Earnings

-$1.31
-$0.87
-$0.44
$0.00
Q1 2019
Q2 2019
Q3 2019
Q4 2019
Q1 2020
Q2 2020
Q3 2020
Estimated
per share
Actual
Expected Nov 10, After Hours

You May Also Like